Britain's medicines regulator approved Cytokinetics' (CYTK.O) drug for a rare heart condition on Thursday, with the country's cost-effectiveness watchdog recommending it for NHS reimbursement, potentially reaching about 6,600 patients.
The drug, under the brand name Myqorzo, is approved for patients with obstructive hypertrophic cardiomyopathy (oHCM), a condition in which the heart muscle becomes abnormally thick and forms an obstruction that can reduce blood flow to the body.
Here are some details:
